Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer.

Authors :: Zhukova OS
Gerasimova GK
Shubina IZh
Kiselevskii MV
Source :: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2007 Aug; Vol. 144 (2), pp. 231-4.
Publication Year :: 2007
Abstract: We studied the ability of lymphokine-activated killer cells to lyse A549 human non-small cell lung cancer cells after preincubation with cisplatin. Lymphokine-activated killer cells obtained after incubation of human blood lymphocytes with interleukin-2 were characterized by high expression of natural killer cell antigens and activation molecules. Lymphokine-activated killer cells produced potent cytotoxic effect on intact A549 cells and lysed tumor cells survived after treatment with cisplatin in concentrations of IC50 and IC30. Cisplatin in noncytotoxic concentrations did not increase lytic activity of lymphokine-activated killer cells.

Subjects :: Carcinoma, Non-Small-Cell Lung immunology
Carcinoma, Non-Small-Cell Lung pathology
Cell Line, Tumor
Combined Modality Therapy
Cytotoxicity, Immunologic
Humans
Immunotherapy, Adoptive
Interleukin-2 pharmacology
Killer Cells, Lymphokine-Activated drug effects
Lung Neoplasms immunology
Lung Neoplasms pathology
Antineoplastic Agents administration & dosage
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung therapy
Cisplatin administration & dosage
Killer Cells, Lymphokine-Activated immunology
Lung Neoplasms drug therapy
Lung Neoplasms therapy

Full Text Access

Tools